The circular pertaining to the anticipated rights offer has recently been published and the shares are now trading ex-rights. The key terms are in line with previous guidance in that shareholders have the right to subscribe for up to twenty shares per each share held as at the 18 May 2019 record date, at a subscription price of 1.52 Canadian cents with the issue being capped at 4.93bn shares, equivalent to gross proceeds of C$75m.
30 May 2019
Rights offer terms confirmed. More pre-clinical data on fibrotic lung conditions for both Ryplazim & PBI 4050
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Rights offer terms confirmed. More pre-clinical data on fibrotic lung conditions for both Ryplazim & PBI 4050
ProMetic Life Sciences (PLI:TSE) | 0 0 1.3% | Mkt Cap: 1,075m
- Published:
30 May 2019 -
Author:
Derren Nathan -
Pages:
8
The circular pertaining to the anticipated rights offer has recently been published and the shares are now trading ex-rights. The key terms are in line with previous guidance in that shareholders have the right to subscribe for up to twenty shares per each share held as at the 18 May 2019 record date, at a subscription price of 1.52 Canadian cents with the issue being capped at 4.93bn shares, equivalent to gross proceeds of C$75m.